EADV Updates Research and Delves Into DNA Behind Dermatology

Damian McNamara

September 26, 2016

VIENNA — The role of genetics in daily dermatology practice, including how genetics can guide treatment decisions, will be the focus of a new in-depth analysis here at the 25th European Academy of Dermatology and Venereology (EADV) Congress.

The basics of genetics — what, why, when, and how — will be addressed by 32 international experts, said Martin Röcken, MD, from the University of Tübingen in Baden-Württemberg, Germany, who is scientific chair of the EADV Congress.

These speakers will provide updates on the complex genetics of psoriasis and atopic eczema, the role of germ-line and acquired mutations in nevi and skin cancers, and the treatment implications of genetics, he reported.

Updates revealed during the Congress could have implications for treatments outside dermatology, said Dr Röcken.

"In just 5 years, primarily topical treatments have been replaced by novel system therapies," he explained. "In many medical areas, dermatology is at the cutting edge of treatment development, which could have a strong influence on many other medical disciplines."

For the dozen new studies that will be presented during the late-breaking abstract session, "scientists and industry have been asked to present their most recent and important clinical work — before publication in major journals," he added.

In just 5 years, primarily topical treatments have been replaced by novel system therapies.

Results from the latest phase 2/3 trials will reveal more about the role of interleukin (IL)-17 and IL-23 antagonist therapy in psoriasis and the way novel cytokine-antagonists offer promise for people with atopic dermatitis.

Other new data being presented will demonstrate the effect immunosuppression can have during pregnancy and the way new treatments could change the course of hyperhidrosis and rare genetic conditions.

"A large number of dermatologists are interested in aesthetics," therefore, 2 days will be devoted to aesthetic dermatology, Dr Röcken told Medscape Medical News.

Aesthetic Medicine

The full-day track on Saturday will look at "the biology, psychology, and therapeutic aspects of aging and beauty," and on "Aesthetic Sunday, we offer separately, for beginners and for specialists,  profound and solid training in important aspects of aesthetic dermatology," he said.

Although Vienna is considered an easy city to navigate, the Congress — with a day of preconference workshops, 3 full days with 16 simultaneous tracks, and a half-day of review and update sessions — might not be.

Dr Röcken offered some advice for the 12,000 or so attendees expected from 40 countries: "One first has to choose the appropriate level of training." The Training and Educational Forum is designed for trainees in dermatology, for example; Review and Updates is for board-certified dermatologists; and the Expert Forum is for academics or specialists in a defined topic.

The sessions have been scheduled to prevent thematic overlap. "Each track addresses a specific topic, from epidemiology and pathogenesis, through the clinic, histopathology, to the classical and advanced therapies," he explained. So complete training on a topic can be attained "in a half-day with eight lectures or an entire day with 16 lectures."

If "forced to choose," Dr Röcken told Medscape Medical News, "I will definitely see all plenary lectures, and I'm especially eager to follow the 2-day genetics track."

Because Vienna has so much to offer visitors, EADV organizers decided not to plan external events. "Vienna is such an attractive city, and so well known, that all of us come with clear expectations," he said. Instead of an additional program, experts will be available to help people "who are looking for special advice to find Mozart, the Hofreitschule, the famous Opera, the castells, or a wonderful café for Saturday morning — before the congress starts."

The latest schedule of scientific events can be found on the EADV Congress website.

Dr Röcken reports financial relationships with AB Science, Abbott Laboratories, Abbott Pharmaceuticals, Almirall Hermal, AstraZeneca, Bayer, Biogen Idec, Bristol-Myers Squibb, Celgene, Galderma, GSK, Hokusai, Janssen-Cilag, Johnson & Johnson, Lilly, Merck & Co., MSD Sharp & Dohme, Novartis, Pfizer, Philogen, Roche, Sanofi-Regeneron, Schering-Plough, and Sterna Biologicals.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: